86.73 0.00 (0.00%)
After hours: 5:08PM EDT
|Bid||86.05 x 800|
|Ask||87.49 x 900|
|Day's range||84.00 - 88.61|
|52-week range||35.25 - 123.99|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||27 Jul 2020 - 31 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||98.57|
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In February, the company announced it was selling approximately $1 billion in senior convertible notes to raise money. Investors were not thrilled at the prospect of Exact Sciences taking on more debt, and this round of fundraising probably contributed to the company's stock dropping by more than 40% in the first quarter. As of this writing, the company's shares are down 6% year to date, while the S&P 500's loss stands at 12.2% over the same period.
Shares of cancer diagnostics leader Exact Sciences (NASDAQ: EXAS) rose higher last week after delivering mixed results on its first-quarter earnings report on May 6. Revenue improved by 115% to $348 million year over year and the company posted a net loss of $105.7 million, or $0.71 per share. The company is one of the many health stocks hit hard by the market plunge in March.
Ladies and gentlemen, thank you for standing by, and welcome to the Exact Sciences First Quarter 2020 Webcast and Conference Call. Thank you, operator, and thank all of you for joining us for Exact Sciences first quarter 2020 conference call. On the call today are Kevin Conroy, the Company's Chairman and CEO; and Jeff Elliott, our Chief Financial Officer.
Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.
Exact Sciences (EXAS) delivered earnings and revenue surprises of -5.26% and 0.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. Jazz Pharmaceuticals (NASDAQ: JAZZ), a maker of sleep therapeutics and oncology drugs, has steadily grown annual revenue for more than a decade, announcing record annual revenue for 2019.
PLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors. “Kim has been a leader and a pioneer in introducing new technologies into the healthcare system impacting the lives of countless patients during her time at Genomic Health and Genentech,” said Serge Saxonov, co-founder and CEO of 10x Genomics.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0.00% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported fourth-quarter net income of $77.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Madison, Wisconsin-based company said it had net income of 54 cents. The results met Wall Street expectations.
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?